August 21, 2025
Tianjin, China – Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as “Jechobio”), a global, clinical stage biopharmaceutical company advancing medicines focusing in oncology, today announced that the National Medical Products Administration (NMPA) has delivered a Notice of Approval for Drug Clinical Trial for JLM019 injection in the treatment of advanced malignant tumors.
“The NMPA’s clearance of our Investigational New Drug application is an important regulatory milestone for Jechobio. JLM019 represents a potential first-in-class next generation IO therapy. We look forward to the expected dosing of the first patient with JLM019 in the next few months,” said Dr. Xiaodong Xiao, CEO of Jechobio.
Jechobio anticipates the enrollment of the first patient in the dose escalation portion of its clinical trial in Q4 2025.
About JLM019
JLM019 is an innovative CD80/PD-1 dual-targeted Fc fusion protein that simultaneously blocks immunosuppression and activates immunostimulation. JLM019 injection exhibits broad-spectrum anti-tumor properties and has demonstrated significant anti-tumor activity in multiple solid tumor models, offering hope for the treatment of patients with advanced cancer.
About Jechobio
Jecho Biopharmaceuticals Co., Ltd., (Jechobio) is a biotech company jointly established by renowned investment companies and Jecho Laboratories, Inc. (USA). Located in Tianjin Sino-Singapore Eco-City since January 2015, Jechobio specializes in research and development, chemistry, manufacturing and controls (CMC), and clinical development of biological therapeutics. Jechobio’s product pipelines are positioned to address unmet clinical needs, focusing on developing a new generation of globally innovative first-in-class (FIC) and best-in-class (BIC) biotherapeutics. Its product portfolio covers monoclonal antibodies, bispecific antibodies, recombinant proteins, oncolytic viruses, immunotoxins, and antibody-drug conjugates. With more than twenty programs in the pipeline, Jechobio has obtained nearly 10 clinical approvals, including those from China’s National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), with the lead product having completed Phase III clinical studies and ready for Biologics License Application (BLA).